Tenet Healthcare Reports Strong Q4 2025 Results with Revenue Growth
Tenet Healthcare's stock surged 3.31% and reached a 52-week high amid a challenging market, with the Nasdaq-100 down 1.02% and the S&P 500 down 0.45%.
The company reported strong Q4 2025 results, with net operating revenues of $5.527 billion, an 8.9% increase year-over-year, and a net income of $371 million, up 16.7%. This performance reflects improved operational efficiency and effective cost control, which are expected to positively impact future shareholder returns. Additionally, Tenet's adjusted EBITDA for Q4 reached $1.183 billion, a 12.8% increase, indicating ongoing improvements in profitability across all business segments.
The strong earnings report has boosted investor confidence, leading to a significant stock price increase despite broader market weakness. Tenet's optimistic outlook for 2026, projecting revenues between $21.5 billion and $22.3 billion, further supports its competitive position in the healthcare sector.
Trade with 70% Backtested Accuracy
Analyst Views on THC
About THC
About the author

- Strong Earnings Report: Tenet Healthcare reported $5.5 billion in revenue for Q4 2025, reflecting approximately 14% year-over-year growth and exceeding market expectations by $60 million, driven by favorable payer mix and increased disease severity.
- Improved Profitability: The company's non-GAAP EPS rose to $4.70, a 37% increase year-over-year, beating Wall Street forecasts by $0.65, with adjusted EBITDA margin reaching 21.4%, up 70 basis points from the previous year, indicating significant profitability enhancement.
- Positive Market Reaction: Tenet's stock surged nearly 19% on Wednesday, reaching an all-time high, which also boosted shares of major competitors like HCA Healthcare and Universal Health Services, reflecting strong market confidence in its financial performance.
- Future Outlook: Despite projecting a 20% decline in overall enrollments for 2026, Tenet anticipates net operating revenue of $21.9 billion, indicating approximately 4% year-over-year growth, showcasing the company's resilience and market confidence amid challenges.
- Revenue and EBITDA Growth: Tenet Healthcare reported net operating revenues of $21.3 billion and consolidated adjusted EBITDA of $4.57 billion for 2025, reflecting a 14% increase over 2024 and exceeding initial expectations by nearly $500 million, indicating strong financial performance and market demand.
- Strong USPI Performance: The USPI segment achieved a 12% growth in adjusted EBITDA to $2.026 billion in 2025, with double-digit same-store volume growth in total joint replacements, demonstrating the company's sustained competitiveness in the healthcare services sector.
- Share Repurchase Program: Over the past three years, Tenet has repurchased approximately 22% of its outstanding shares for around $2.5 billion, reflecting the company's confidence in its value and creating additional value for shareholders.
- 2026 Guidance: Management projects adjusted EBITDA for 2026 to be between $4.485 billion and $4.785 billion, despite facing a $250 million impact from the expiration of tax credits, indicating a commitment to growth through ongoing M&A and service line expansion.
- Earnings Beat: Diodes reported an adjusted EPS of 34 cents, surpassing market expectations of 32 cents, indicating strong profitability that boosts investor confidence.
- Sales Growth: The company's quarterly sales reached $391.578 million, exceeding the anticipated $385.560 million, suggesting sustained demand for its products that could drive future revenue growth.
- Stock Surge: Diodes shares jumped 31.8% to $81.32 on Wednesday, reflecting a positive market reaction to its earnings report, which may attract more investor interest.
- Market Performance: U.S. stocks were slightly higher, with the Dow Jones gaining around 0.1% on Wednesday, indicating cautious optimism about the economic outlook that could provide a favorable environment for other companies.
- Strong Sales Performance: Tenet Healthcare reported fourth-quarter sales of $5.527 billion, reflecting an 8.9% year-over-year increase that surpassed the consensus estimate of $5.472 billion, indicating robust growth in the healthcare services sector.
- Improved Profitability: Adjusted earnings per share rose to $4.70 from $3.44 a year ago, exceeding the consensus of $4.05, which highlights effective cost management and revenue growth strategies implemented by the company.
- Segment Performance: The ambulatory segment saw a 13.8% revenue increase to $1.43 billion, driven by strong growth in same-facility net patient services and expanded service lines, showcasing the company's adaptability in high-demand areas.
- Positive Outlook: Tenet projects 2026 revenues between $21.5 billion and $22.3 billion, above the consensus of $22.21 billion, reflecting confidence in market demand and the company's execution capabilities moving forward.

Healthcare Shares Decline: Tenet Healthcare shares have dropped by 2.2%.
Revenue Forecast Adjustment: The company's revenue forecast for 2026 is now projected to be below previous estimates.
- Earnings Beat: Tenet Healthcare reported a Q4 non-GAAP EPS of $4.70, surpassing expectations by $0.65, indicating robust profitability growth for the company.
- Significant Revenue Growth: Q4 revenue reached $5.53 billion, up 14% year-over-year, exceeding forecasts by $60 million, reflecting strong performance in patient services and facility acquisitions.
- Surgical Business Strength: The surgical segment's same-facility net patient service revenues increased by 7.2% in Q4, with case volume up 1.6% and net revenue per case rising by 5.5%, driven by higher acuity and favorable payer mix.
- Optimistic Outlook: The FY 2026 adjusted EBITDA is projected to be between $4.485 billion and $4.785 billion, indicating the company's confidence in future performance and potential for continued growth.








